Asset
DARINAPARSIN
ALAUNOS THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00592046 | phase1 | completed | 2005-05-01 | 2008-06-01 | Alaunos Therapeutics | A Phase I Trial of ZIO-101 in Hematologic Cancers |
| NCT00591396 | phase1 | completed | 2005-07-01 | 2008-07-01 | Alaunos Therapeutics | A Phase I Trial of ZIO-101 in Solid Tumors |
| NCT00423306 | phase2 | terminated | 2007-05-01 | 2008-08-09 | Alaunos Therapeutics | A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma |
| NCT00421213 | phase2 | terminated | 2006-12-29 | 2009-06-30 | Alaunos Therapeutics | Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers |
| NCT01139359 | phase1 | withdrawn | 2010-06-01 | 2011-06-01 | Alaunos Therapeutics | Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma |
FDA applications (0)
This company has no applications containing this asset.